[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"memory\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:memory":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,18,0,[8,44,73,104,131,156,181,225,264,289,320,345,367,396,420,443,470,492],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100645177","cannabis-observations-on-brain-waves-retrieval-and-attention-experiment-4-100645177",false,"NCT07679581","Cannabis Observations on Brain Waves, Retrieval, and Attention: Experiment 4","Cannabis and Memory","COBRA 4","1. Must be between the ages of 21 and 40 and provide informed consent;\n2. Must be right-handed (Laterality Quotient \\> 60 on Edinburgh Handedness Inventory - Short Form136);\n3. Heavy users (HU) in Experiments 1, 2, 3, and 4:\n\n   1. Must use cannabis at least 4 days during the month;\n   2. Must be a cannabis user for at least a year;\n4. Non-users (NU) in Experiment 2:\n\n   1. Must not have used cannabis for prior 6 months;\n   2. Must have at least one episode of lifetime cannabis use;\n5. Must self-report not using other illicit recreational drugs (e.g., cocaine, benzodiazepines (non-prescription), opiates (non-prescription), MDMA, sedatives, or methamphetamine) in the past 30 days, during the Pre-Screening;\n6. Must not test positive on a urine toxicology test for drugs of abuse at the Baseline Appointment (TDS);\n7. Must not be using psychotropic medications, however anti-depressant, non-benzodiazepine anti-anxiety, and ADHD medications are ok. ADHD medication users must be willing to abstain from ADHD medication use on appointment days; ADHD medications, even extended-release forms, are short acting and medication\" holidays\" (e.g., on weekends and holidays) are routine in individuals prescribed ADHD medications, without adverse effects.\n8. Must not be a regular nicotine user (≤4 days per week; cigarette, E-cigs, or smokeless);\n9. Must not have used caffeine or nicotine (cigarette, E-cigs, or smokeless) for 4 hours;\n10. Must have a breath alcohol level of 0 at screening (to sign consent form);\n11. Must not be actively seeking or in treatment for any substance use disorder (drug use levels will be carefully monitored via Timeline Follow Back (TLFB) throughout the study to assess any confounding influences of drug or alcohol use;\n12. Female subjects must not be or trying to become pregnant (as indicated by a pregnancy test \\& screening form administered at Baseline);\n13. Must not be in treatment for psychotic disorder or bipolar disorder; or have a history with these disorders;\n14. Must not have any physical characteristics (e.g., thick hair, head size exceeding the limit of the net, dyed hair) or experience any technical difficulties during testing that result in a poor-quality EEG recording.\n15. Participants in Experiment 4 a. Must not have participated in Experiment 3",true,"ALL","21 Years","40 Years",{"count":22,"type":23},64,"ESTIMATED","OBSERVATIONAL","This study investigates the impact of ∆9-tetrahydrocannabinol (THC) and cannabidiol (CBD) on recognition memory in healthy, regular cannabis users. Participants complete the same recognition memory task after self-administering one of two different strains of cannabis flower one day and while not intoxicated another day. Event-related potentials (ERPs) are measured via electroencephalogram (EEG) during the recognition memory task. Blood is collected to quantify THC and CBD exposure. Participants also complete self-report measures of medical history, sleep quality, subjective cognitive function, physical activity, psychological functioning, substance use, and acute drug effects.",[27,28,29],"Cannabis","Memory","Electroencephalography",[27,28,29],"RECRUITING","2026-06-29",{"date":34,"type":35},"2026-07-01","ACTUAL",{"date":37,"type":35},"2025-12-10",{"date":39,"type":23},"2027-05-31",{"name":41,"class":42},"L. Cinnamon Bidwell","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":17,"sex":18,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":56,"briefSummary":58,"conditions":59,"keywords":60,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":72},"100543071","longitudinal-investigation-of-sleep-memory-and-brain-development-across-the-nap-transition-100543071","NCT06351098","Longitudinal Investigation of Sleep, Memory, and Brain Development Across the Nap Transition","HSR","Inclusion Criteria:\n\n1. 36-60 months at the time of enrollment\n2. must be a habitual napper (defined as napping 5 or more days\u002Fweek on average for the past month)\n3. must sleep independently (not bedsharing; in order to maintain consistent sleep not interrupted by others)\n\nExclusion Criteria:\n\n1. diagnosis of any sleep disorder (other than mild parasomnia which is routine at this age) past or present (Child's Sleep Habit Questionnaire)\n2. current use of psychotropic or sleep-altering medications (Developmental, Health, and Environment Questionnaire)\n3. traveling beyond 1 time zone within 1 month prior to testing (phone screening)\n4. fever or symptoms of respiratory illness at the time of testing (phone screening)\n5. physical handicap which interferes with assessments (vision, hearing impairment; phone screening)\n6. diagnosed developmental disability (Developmental, Health, and Environment Questionnaire)\n7. history of neurological injury such as history of seizures, brain tumor, or stroke (phone screening)\n8. presence of metal in the body (e.g., implant of any form) or other contraindication for MRI (e.g., claustrophobia, which is rare at this age).\n9. external influences on nap habits (e.g., inability to nap due to school or caregiver schedule or interfering activities during a typical naptime) including if the child will enroll in full-day kindergarten by the end of the study. Caregivers will also be queried for the presence of interfering activities throughout enrollment (e.g., ecological momentary assessment (or EMA), sleep diaries at each wave).","36 Months","60 Months",{"count":54,"type":23},180,"INTERVENTIONAL",[57],"NA","To examine the relations between sleep (nap transitions, sleep physiology), memory, and brain development longitudinally, the researchers will assess n=180 children (in order to acquire n=152 usable data sets) who are 36-54 months of age and habitual nappers at enrollment. In each wave, the researchers will assess memory, memory change over a nap and equivalent waking interval, sleep physiology of the nap, and brain structure and function (using Magnetic Resonance Imagining or MRI). Additionally, overnight sleep physiology will be assessed in all participants. Waves will take place approximately every 6 months. For all children, three waves will be collected. With these data, the researchers will address the following aims:\n\n* Examine neural markers that predict the sleep transition (Aim 1);\n* Examine changes in sleep-dependent memory processing (mnemonic discrimination) over both nap and overnight sleep intervals, across the sleep transition (Aim 2);\n* Examine changes in sleep microstructure in both nap and overnight sleep across the sleep transition (Aim 3)\n* Examine interrelations among brain, memory and sleep microstructure across the sleep transition (Aim 4)",[28],[61,62],"Sleep","Brain development","2026-06-02",{"date":65,"type":35},"2026-06-04",{"date":67,"type":35},"2023-11-05",{"date":69,"type":23},"2028-06",{"name":71,"class":42},"University of Maryland, College Park",2,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":17,"sex":18,"minAge":80,"maxAge":81,"enrollmentInfo":82,"targetDuration":4,"studyType":55,"phases":84,"briefSummary":85,"conditions":86,"keywords":90,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":4},"100637231","unconscious-mind-training-100637231","NCT07597603","Unconscious Mind Training","H22 - Unconscious Mind Training and Memory Encoding","Inclusion Criteria:\n\n* Can read and write\n* Willing and able to follow the requirements of the protocol\n\nExclusion Criteria:\n\n\\- Medical instability, restlessness, or other factors that would compromise data acquisition","10 Years","75 Years",{"count":83,"type":23},100,[57],"H22 - Unconscious Mind Training and Memory Encoding\n\nPhase I\n\nThe core problem this clinical trial, H22, seeks to address is the pervasive challenge of modifying deeply ingrained, often unconscious, unwanted behaviors within the general population. Many individuals struggle with habits or actions that negatively impact quality of life, productivity, or well-being, yet conventional methods often fall short due to the unconscious nature of these behaviors.\n\nSpecifically, the trial aims to investigate the efficacy of H22, a novel intervention designed to engage and train the unconscious mind, in mitigating these unwanted behaviors. The central hypothesis guiding this research is that H22 training will empower volunteers to significantly reduce the frequency and intensity of identified unwanted behaviors.",[87,28,88,89],"Memory Encoding","Behavior Change Interventions","Habits",[91,92,93],"Behavior","Cognitive ability","Unconscious mind","NOT_YET_RECRUITING","2026-05-31",{"date":97,"type":35},"2026-06-03",{"date":99,"type":23},"2027-01",{"date":101,"type":23},"2028-01",{"name":103,"class":42},"Dream Video LLC",{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":110,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":18,"minAge":20,"maxAge":112,"enrollmentInfo":113,"targetDuration":4,"studyType":55,"phases":115,"briefSummary":116,"conditions":117,"keywords":119,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":43},"100639024","percepta-for-cognitive-optimization-100639024","NCT07612449","Percepta for Cognitive Optimization","Percepta for Cognitive Optimization: A 6-Month Randomized Controlled Trial With Neurocognitive, Wearable, and Participant-Reported Outcomes in Adults With Mild Cognitive Impairment","PFCO","Inclusion Criteria:\n\n* Demographics: Must be English-speaking and currently residing in the United States.\n* Cognitive Status: Must have self-reported cognitive impairment, defined specifically by a Montreal Cognitive Assessment (MoCA) score of less than 25.\n* Technology Access: Must own an Oura Ring, maintain an active membership throughout the study, and have consistent access to a smartphone for app-based surveys and data syncing.\n* Medical Stability: Must be in good general health and medically stable, with no significant health changes in the three months prior to enrollment.\n* Consent and Compliance: Must provide signed informed consent and demonstrate a willingness to comply with all study procedures, including assessments and lifestyle considerations.\n\nExclusion Criteria:\n\n* Neurological and Psychiatric Disorders: A self-reported diagnosis of dementia, Alzheimer's disease, Parkinson's disease, depressive disorders, bipolar disorder, schizophrenia, epilepsy, multiple sclerosis, or substance use disorder. This also includes a history of stroke, traumatic brain injury (TBI), intracranial hemorrhage, or seizure disorders.\n* Medication Use: Current use of cognitive-affecting medications or supplements, such as donepezil, memantine, methylphenidate, benzodiazepines, antipsychotics, or nootropics.\n* Allergies: Known allergy or sensitivity to cat's claw or oolong tea,. Reproductive Status: Currently pregnant, breastfeeding, or planning to become pregnant within the next 12 months.\n* Genetic Risk: Known carrier of the APOE-4 allele.\n* Recent Study Participation: Enrollment in another clinical trial or intervention study within the past 30 days.","85 Years",{"count":114,"type":23},154,[57],"This Phase 1, randomized, double-blind, placebo-controlled trial evaluates the cognitive and neurophysiological effects of a dietary supplement containing cat's claw (Uncaria tomentosa) bark extract and oolong tea extract, in adults aged 40-85 with self-reported mild cognitive impairment (MCI).\n\nThe study employs a decentralized design leveraging remote monitoring technologies. Participants will self-administer the study supplement or a matched placebo daily for 6 months. The primary outcome is cognitive performance assessed by digital Montreal Cognitive Assessment (MoCA) at baseline, Month 3, and Month 6. Secondary outcomes include objective sleep and autonomic metrics from Oura Ring wearables (heart rate variability, sleep architecture) and self-reported brain health using the Brain Health Index.\n\nAn exploratory sub-study will measure plasma biomarkers of neurodegeneration (pTau-217) at baseline and Month 6 in a subset of participants to explore potential mechanisms of action.\n\nThe study aims to provide preliminary evidence for Percepta's efficacy in improving cognitive function and supporting brain health in individuals with MCI, while evaluating safety and biological plausibility through mechanistic biomarkers.",[118,28],"Mild Cognitive Impairment (MCI)",[120,121],"Supplement","MCI","2026-05-23",{"date":124,"type":35},"2026-05-28",{"date":126,"type":23},"2026-06-01",{"date":128,"type":23},"2026-12-31",{"name":130,"class":42},"Cerebrum DAO Association",{"id":132,"slug":133,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":4,"eligibilityCriteria":137,"healthyVolunteers":17,"sex":18,"minAge":138,"maxAge":4,"enrollmentInfo":139,"targetDuration":4,"studyType":55,"phases":141,"briefSummary":143,"conditions":144,"keywords":4,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":4},"100628434","early-phase-1-memory-enhancement-in-aging-with-optimal-dosing-100628434","NCT07461584","Memory Enhancement in Aging With Optimal Dosing","Personalized Memory Enhancement in Aging: Pattern-Optimized tACS With Closed-Loop Precision Modulation","Inclusion Criteria:\n\n* 65 years of age or older\n* normal or corrected-to-normal vision\n* color vision\n\nExclusion Criteria:\n\n* pregnant\n* metal implants in head\n* implanted electronic devices\n* history of neurological problems or head injury\n* skin sensitivity\n* claustrophobia\n* dementia (normal Montreal Cognitive Assessment \\> 25)\n* depression (normal Geriatric Depression Scale \\\u003C 10)\n* history of psychosis\n* cognitive deficits (MoCA\\>25)\n* any psychoactive medication","65 Years",{"count":140,"type":23},240,[142],"EARLY_PHASE1","This project optimizes high-resolution tACS to improve memory in healthy older adults, advancing drug-free approaches for ADRD. We test stimulation schedules and develop an adaptive, brain-guided tACS system to strengthen memory-supporting networks.",[145,146,28],"Aging","Noninvasive Brain Stimulation","2026-04-01",{"date":149,"type":35},"2026-04-07",{"date":151,"type":23},"2026-05-01",{"date":153,"type":23},"2031-01-31",{"name":155,"class":42},"Boston University Charles River Campus",{"id":157,"slug":158,"hasResults":11,"nctId":159,"briefTitle":160,"officialTitle":161,"acronym":162,"eligibilityCriteria":163,"healthyVolunteers":17,"sex":18,"minAge":164,"maxAge":165,"enrollmentInfo":166,"targetDuration":4,"studyType":55,"phases":168,"briefSummary":169,"conditions":170,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":179,"locationsCount":43},"100628948","synchronization-of-theta-to-influence-memory-100628948","NCT07468279","Synchronization of Theta to Influence Memory","Effects of Non-Invasive Brain Stimulation on Task Performance","STIM","Inclusion Criteria:\n\n* 18 years and older\n* Fluent in English\n* Normal or corrected-to-normal vision\n* Willing to be photographed\n\nExclusion Criteria:\n\n* Must not have ever had an injury to the head that's caused you to be knocked out for a period of time (e.g., from a fall, blow to the head, road traffic accident).\n* Must not have an uncorrected vision or physical disability that interferes with your ability to see stimuli presented briefly on a computer screen or click a mouse button rapidly.\n* Must not have a history of epilepsy, convulsions, or seizures (except childhood febrile seizures).\n* Must not have a history of fainting or syncope.\n* For female participants, they must not be pregnant and\u002For must not think they might be pregnant.\n* Must not have skin problems like eczema, dermatitis, or open wounds on the scalp.\n* Must not have had prior brain surgery.\n* Must not have any metal located in the head\u002Fneck (except for dental fillings).\n* Must not have any devices or other implants located in\u002Fnear their head. This includes cochlear implants and aneurysm clips, cardiac pacemaker, or any other implanted electronic device.\n* Must not have a current (active) alcohol or substance use disorder, must have no recent history of withdrawal symptoms, and must be able to safely abstain from alcohol and non-prescribed\u002Fillicit drugs for at least 24 hours before the session.\n* Must not have any alcohol on the day of the session, must limit alcohol consumption to no more than 2 drinks (if legally permitted) in the prior 24 hours, and must not use any non-prescribed or illicit drugs in the 24 hours before the session.\n* Must not be sick with a fever, sleep-deprived, or feel dizzy, unwell, or intoxicated.\n* Must also have eaten and had fluids but not have consumed more caffeine than they typically consume.\n* Must not be taking anticonvulsant\u002Fanti-epileptic drugs or have ever taken them within their lifetime.\n* Must not be taking benzodiazepines or have taken them within the past 3 months.\n* Must not have had a recent change (start, stop, dose change) for any psychiatric\u002Fpsychotropic medications within the past 3 months.\n* Must not be taking Bupropion (Wellbutrin, Zyban), Tricyclic antidepressants (e.g., amitriptyline, imipramine, clomipramine, etc.), Antipsychotics (clozapine; chlorpromazine, haloperidol, etc.), or Tramadol or have taken them within the past 3 months.\n* Must not have experienced cardiac problems, fibrillation, or have taken medications associated with cardiac conditions within the past 3 months.\n* Must not meet the diagnostic threshold for Autism Spectrum Disorder, Intellectual Disability, or Psychotic Disorders.","18 Years","59 Years",{"count":167,"type":23},90,[57],"This study aims to clarify relations between brain oscillations and two cognitive functions: cognitive control and memory.",[171,28],"Cognitive Control","2026-03-16",{"date":174,"type":35},"2026-03-17",{"date":176,"type":35},"2026-03-13",{"date":178,"type":23},"2031-01",{"name":180,"class":42},"Florida International University",{"id":182,"slug":183,"hasResults":11,"nctId":184,"briefTitle":185,"officialTitle":186,"acronym":187,"eligibilityCriteria":188,"healthyVolunteers":11,"sex":18,"minAge":164,"maxAge":4,"enrollmentInfo":189,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":191,"conditions":192,"keywords":205,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":217,"startDateStruct":218,"completionDateStruct":220,"leadSponsor":222,"locationsCount":4},"100629619","non-invasive-detection-and-preservation-of-neurocognitive-signals-in-the-peri-death-period-using-brain-computer-interface-and-artificial-intelligence-100629619","NCT07477028","Non-Invasive Detection and Preservation of Neurocognitive Signals in the Peri-Death Period Using Brain-Computer Interface and Artificial Intelligence","Feasibility of Non-Invasive Detection and Preservation of Neurocognitive Signals in the Peri-Death Period Using Brain-Computer Interface and Artificial Intelligence: A Prospective Observational Study (NeuroCogPresv)","NeuroCogPresv","Inclusion Criteria:\n\n1. Adults ≥18 years with terminal illness or severe acute trauma\n2. Do-not-resuscitate (DNR\u002FDNI) order in place\n3. Surrogate decision-maker available and willing to provide informed consent\n4. Expected survival ≤7 days (physician estimate)\n\nExclusion Criteria:\n\n1. Brain death already declared \\> 24 hours prior to enrollment\n2. Contraindication to EEG\u002FBCI headset placement (e.g., severe scalp injury)\n3. Patient lacks a legally authorized representative",{"count":190,"type":23},20,"Background: Recent electroencephalography (EEG) data indicate that the transition from clinical death to cellular death is marked by highly organized neurophysiological events, including significant surges in gamma-band power, cross-frequency coupling, and distinct spreading depolarization waves. This prospective, observational feasibility study utilizes rapid-deployment, high-density, noninvasive BCI hardware paired with proprietary AI analytics to detect, classify, and securely archive these terminal neurocognitive signals.\n\nObjectives: (1) Quantify transient gamma-band activity and cross-frequency connectivity post-clinical death; (2) Validate the efficacy of machine learning models for real-time signal classification in high-noise clinical environments; (3) Establish a highly secure, encrypted bio-informational archive of peri-life EEG data.\n\nDesign: Prospective, open-label, multicenter, observational cohort (n\\>20).",[193,194,195,196,197,198,29,199,200,201,202,28,203,204],"Terminal Illness","End-of-Life Care","Death","Brain Death","Death Anxiety","Consciousness","Gamma Oscillations","Near-Death Phenomena","Cognitive","Cognition","EEG","Severe Acute Trauma",[206,207,208,195,199,202,198,209,210,211,28,212,213,214,215],"AI","BCI","Brain Computer Interface","Pefi-death","Brain death","Reservation","Life","Life experience","Transfer","Convergence","2026-03-12",{"date":174,"type":35},{"date":219,"type":23},"2026-09-01",{"date":221,"type":23},"2035-09-30",{"name":223,"class":224},"Noah Tech, Corp.","INDUSTRY",{"id":226,"slug":227,"hasResults":11,"nctId":228,"briefTitle":229,"officialTitle":229,"acronym":230,"eligibilityCriteria":231,"healthyVolunteers":17,"sex":18,"minAge":138,"maxAge":112,"enrollmentInfo":232,"targetDuration":4,"studyType":55,"phases":234,"briefSummary":235,"conditions":236,"keywords":244,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":256,"lastUpdatePostDateStruct":257,"startDateStruct":258,"completionDateStruct":260,"leadSponsor":262,"locationsCount":43},"100628795","l-serine-and-strength-training-in-the-elderly-100628795","NCT07466290","L-serine and Strength Training in the Elderly","AAAging","Inclusion Criteria:\n\n* Men and women between the ages of 65 and 85\n* Mini-Mental-State \\>23\n* Independently mobile, without aids (walker, cane, etc.)\n\nExclusion Criteria:\n\n* Chronic diseases that contraindicate medical training therapy\n* Regular strength training (\\>1x\u002Fweek) in the last 6 months before confinement\n* Frailty Index ≥ 3\n* Lack of written consent to test physical performance\n* Regular use of Cortison-containing medications or Antibiotika\n* MR-specific exclusion criteria: claustrophobia, metal equipment or other magnetic Material in or on the body\n* Non-compliance with the study protocol: \\\u003C70% of the planned L-serine administration, \\\u003C70% of the strength training",{"count":233,"type":23},126,[57],"This study investigates whether taking the amino acid L-serine, either alone or in combination with targeted strength training, can have a positive effect on mental performance, brain function, and physical fitness in older people.\n\nHealthy, independent women and men aged 65 to 85 are eligible to participate. Participants will be randomly assigned to one of three groups: placebo, L-serine, or L-serine combined with strength training.\n\nCognitive tests, physical performance tests, and blood and brain tests will be conducted over a period of 48 weeks. The aim is to gain a better understanding of how nutrition and exercise can contribute to healthy aging.",[237,238,239,240,241,242,202,28,243],"Brain Health","Longevity","Cognitive Performance","Strength Training Effects","Healthy Ageing","Ageing","Muscle Strength",[241,245,246,247,248,249,250,28,251,252,29,253,254,255],"Brain ageing","Older adults","L-serine supplementation","Resistance training","Cognitive function","Cognitive ageing","Hippocampus","Magnetic resonance imaging","Brain connectivity","Muscle strength","Synaptic plasticity","2026-03-06",{"date":216,"type":35},{"date":259,"type":23},"2026-03",{"date":261,"type":23},"2028-12",{"name":263,"class":42},"University of Vienna",{"id":265,"slug":266,"hasResults":11,"nctId":267,"briefTitle":268,"officialTitle":269,"acronym":270,"eligibilityCriteria":271,"healthyVolunteers":11,"sex":18,"minAge":164,"maxAge":272,"enrollmentInfo":273,"targetDuration":4,"studyType":55,"phases":275,"briefSummary":276,"conditions":277,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":280,"lastUpdatePostDateStruct":281,"startDateStruct":283,"completionDateStruct":285,"leadSponsor":287,"locationsCount":43},"100558436","prediction-of-anxiety-and-memory-state-100558436","NCT06551090","Prediction of Anxiety and Memory State","Developing the Context-Aware Multimodal Ecological Research and Assessment (CAMERA) Platform for Continuous Measurement and Prediction of Anxiety and Memory State","CAMERA","Inclusion Criteria:\n\n* Patients must have known or suspected Temporal Lobe Epilepsy.\n* Native or proficient in speaking English or Spanish.\n* Stereoelectroencephalography (sEEG) cases: The implant plan must include hippocampal head, body, and tail electrodes either unilaterally or bilaterally.\n* 7th grade reading level (minimum level considered literate for adults)\n\nExclusion Criteria:\n\n* Hearing impaired (i.e., not corrected with a hearing aid)\n* Unable to read the newspaper at arm's length with corrective lenses.\n* Objective intellectual impairment (estimated IQ \\\u003C 70)\n* Any history of Electroconvulsive Therapy or psychosis (except postictal psychosis for patients)\n* Psychotic disorder (lifetime)\n* Current Anxiety disorder, Major Depressive Disorder, or Bipolar Disorder\n* Neurodegenerative diseases, presence of widespread brain lesions, language problems (other than naming difficulty)\n* Medical conditions that could potentially affect cognitive performance (e.g., human immunodeficiency virus (HIV) infection, cancer with metastatic potential).\n* Acute renal failure or end-stage renal disease","55 Years",{"count":274,"type":23},40,[57],"The purpose of this study is to look at how signals in the brain, body, and behavior relate to anxiety and memory function. This project seeks to develop the CAMERA (Context-Aware Multimodal Ecological Research and Assessment) platform, a state-of-the-art open multimodal hardware\u002Fsoftware system for measuring human brain-behavior relationships.\n\nThe R61 portion of the project is designed to develop the CAMERA platform, which will use multimodal, passive sensor data to predict anxiety-memory state in patients undergoing inpatient monitoring with intracranial electrodes for clinical epilepsy, as well as to build CAMERA's passive data framework and active data framework.",[278,28,279],"Anxiety","Epilepsy","2026-01-26",{"date":282,"type":35},"2026-01-28",{"date":284,"type":35},"2024-07-23",{"date":286,"type":23},"2026-12-01",{"name":288,"class":42},"Columbia University",{"id":290,"slug":291,"hasResults":11,"nctId":292,"briefTitle":293,"officialTitle":294,"acronym":295,"eligibilityCriteria":296,"healthyVolunteers":11,"sex":18,"minAge":164,"maxAge":297,"enrollmentInfo":298,"targetDuration":4,"studyType":55,"phases":299,"briefSummary":300,"conditions":301,"keywords":305,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":311,"lastUpdatePostDateStruct":312,"startDateStruct":314,"completionDateStruct":316,"leadSponsor":318,"locationsCount":72},"100616343","effects-of-exercise-and-sleep-on-motor-learning-and-functional-abilities-in-multiple-sclerosis-100616343","NCT07304375","Effects of Exercise and Sleep on Motor Learning and Functional Abilities in Multiple Sclerosis","Effects of Aerobic Exercise and Daytime Sleep on Neurorehabilitation and Functional Abilities in Multiple Sclerosis: Evidence of Training the Brain in Neurorehabilitation","ExSiMS","Inclusion Criteria:\n\n* Competent individuals (aged 18-70) diagnosed with early relapsing-remitting MS\n* Expanded Disability Status Score, 1 \\\u003C EDSS \\\u003C 4.5\n* MRC muscle strength ≥ 4+ in the dominant hand\n\nExclusion Criteria:\n\n* Implanted devices, such as pacemakers or stimulators\n* Epilepsy or neuromuscular diseases","70 Years",{"count":190,"type":23},[57],"The ExSiMS study is a randomized, controlled crossover study including 20 individuals (18-70 years) diagnosed with relapsing remitting Multiple Sclerosis (MS) This project investigates, through behavioral and neurophysiological measurements, how aerobic exercise on an ergometer bike and sleep in the form of a nap and overnight sleep may enhance cortical motor skill learning evaluated by a complex hand motor skill test and thereby improve functional capacity in individuals with MS. Beyond the effect on motor skill learning, the project investigate the effect on electroencephalography (EEG) - electromyography (EMG) coherence.\n\nThe study hypothesizes that individuals with neurological conditions, such as multiple sclerosis (MS), may experience beneficial effects on specific motor rehabilitation through systematically planned cardiovascular exercise and sleep scheduling, due to positive impacts on memory consolidation.\n\nAims:\n\n* Investigate the brain's neurophysiological responses and memory effects following a training intervention and, separately, sleep, in the form of a power nap, in individuals with MS.\n* Examine whether these effects persist beyond the few days previously observed in healthy individuals by implementing a longer-term intervention.\n* Explore whether the training effect is influenced by disease activity in the brain, such as during relapses and during immunosuppressive treatment.\n* Assess whether the presence of abnormally reduced cognitive endurance (fatigue) affects the impact of the intervention involving exercise and sleep.\n\nThe study is based on documented positive effects of physical activity and sleep in both young and older adults, as well as in individuals recovering from stroke. The research thus offers promising perspectives for broader applications within neurorehabilitation, and particularly for MS, as the disease is associated with functional impairments. At the same time, both physical exercise and sleep represent meaningful interventions that should be thoughtfully integrated into rehabilitation strategies.",[302,61,303,28,304],"Exercise","Motor Learning","Multiple Sclerosis",[306,307,61,308,303,28,309,310],"Aerobic Exercise","Daytime Sleep","Learning Ability","Cognitive Function","Neurorehabilitation","2026-01-05",{"date":313,"type":35},"2026-01-08",{"date":315,"type":35},"2025-12-01",{"date":317,"type":23},"2028-11-30",{"name":319,"class":42},"Zealand University Hospital",{"id":321,"slug":322,"hasResults":11,"nctId":323,"briefTitle":324,"officialTitle":325,"acronym":326,"eligibilityCriteria":327,"healthyVolunteers":17,"sex":18,"minAge":164,"maxAge":272,"enrollmentInfo":328,"targetDuration":4,"studyType":55,"phases":329,"briefSummary":330,"conditions":331,"keywords":333,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":336,"lastUpdatePostDateStruct":337,"startDateStruct":339,"completionDateStruct":341,"leadSponsor":343,"locationsCount":43},"100591876","virtual-contexts-for-affective-modulation-100591876","NCT06986122","Virtual Contexts for Affective Modulation","Controllability of Virtual Contexts for the Modulation of the Affective Experience","VCAM","* No self-reported current or history of depression, bipolar disorder, or other psychiatric diagnosis\n* No self-reported current seizure disorder (i.e., seizure within past 10 years), or history of stroke or other major neurological diagnosis\n* No self-reported current chronic pain, or acute pain within three months of the study period\n* No current migraine disorder (i.e., 15 headache days or more in 1 month)\n* No use of central nervous system-effective medication or other medication for neurological\u002Fpsychiatric treatment\n* No self-reported substance abuse within the last six months\n* No contraindication to MRI (e.g., pregnancy, claustrophobia, pacemakers, ear\u002Fcochlear implants, shrapnel injuries, clips, or other ferromagnetic\u002Felectrical objects\u002Fdevices, diagnosed brain abnormality such as tumor, or skin lesions on the scalp.)\n* No contraindications for induced pain (e.g., no heart disease, high blood pressure, heart surgery, heart problems of any kind, severe asthma, respiratory problems of any kind, fibromyalgia, Raynaud's Syndrome or Disease, chronic pain, diabetes)\n* Participants must be capable of performing experimental tasks (e.g., are able to read), are fluent or native speakers of English\n* Participants must be able to tolerate the maximum level of thermal pain stimuli (for thermal stimuli)",{"count":190,"type":23},[57],"This study investigates how spatial context and perceived controllability modulate pain, affective states such as anxiety, and motivated behavior. The study examines how control over pain and threat-related environments influences pain perception, state anxiety, associated autonomic responses, and behavior. The main questions it aims to answer are:\n\nDoes having control over pain within specific contexts alter how much pain people feel-even when the stimulus intensity remains constant? How do different types of environments (safe, controllable, or uncontrollable) shape pain-related brain activity, subjective anxiety, and physiological arousal? How do people perform cognitively demanding or distracting tasks (and retain their memory) when under threat versus when in control? Lastly, how do these learned associations with spatial contexts persist or adapt when environmental contingencies are explicitly changed?\n\nTaken together, exploration of these factors may lay the groundwork for understanding how placebo-related mechanisms-including perceived control, contextual learning, emotional engagement, and distraction-interact to shape pain and anxiety in complex environments.",[332,278,28],"Pain Control",[334,335],"Place conditioning","controllability of pain","2025-10-29",{"date":338,"type":35},"2025-10-31",{"date":340,"type":35},"2025-10-28",{"date":342,"type":23},"2029-06-15",{"name":344,"class":42},"Trustees of Dartmouth College",{"id":346,"slug":347,"hasResults":11,"nctId":348,"briefTitle":349,"officialTitle":350,"acronym":4,"eligibilityCriteria":351,"healthyVolunteers":17,"sex":18,"minAge":272,"maxAge":4,"enrollmentInfo":352,"targetDuration":4,"studyType":55,"phases":354,"briefSummary":355,"conditions":356,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":359,"lastUpdatePostDateStruct":360,"startDateStruct":361,"completionDateStruct":363,"leadSponsor":365,"locationsCount":43},"100608955","cognitive-vitality-pilot-study-100608955","NCT07208279","Cognitive Vitality Pilot Study","Effects of Dietary Supplement Intervention on Cognitive Function and Psychological Well-Being","Inclusion Criteria:\n\n* Adults aged 55 years and older\n* Live independently,\n* Self-report as healthy\n* Adequate vision\n* Fluent in English\n* No history of mild cognitive impairment\n* Currently not taking dietary supplements with the same active ingredients in Axolt or naturally flavored water\n* A Montreal Cognitive Assessment \\[12\\] (MOCA) score ≥ 24\n* Able to provide written informed consent, and medical clearance to participate.\n\nExclusion Criteria:\n\n* Previous participation in a cognitive dietary supplement study in the last 12 months\n* A score of \\\u003C 24 on the Montreal Cognitive Assessment (MoCA) as a potential risk for obtaining informed consent\n* History of seizures\n* Epilepsy\n* Parkinson's disease\n* History of severe head trauma\n* Uncontrolled hypertension\n* On psychoactive medications\n* Substance abuse\n* Unwilling or unable to discontinue current dietary supplements with similar ingredients\n* Planned surgery during the study period\n* Medications known to interact with active ingredients with Axolt\n* Minors and prisoners will be excluded.",{"count":353,"type":23},16,[57],"This study's purpose is to evaluate the effects of a dietary supplement on cognitive function and psychological well-being in community-dwelling older adults aged 55+. The study involves taking a commercially available dietary supplement daily for 45 days. A 45-minute assessment will be conducted at the beginning and again at the end of the study.",[145,357,202,28,358],"Healthy Aging","Brain","2025-10-27",{"date":340,"type":35},{"date":362,"type":35},"2025-09-01",{"date":364,"type":23},"2026-08-11",{"name":366,"class":42},"Arizona State University",{"id":368,"slug":369,"hasResults":11,"nctId":370,"briefTitle":371,"officialTitle":372,"acronym":373,"eligibilityCriteria":374,"healthyVolunteers":11,"sex":18,"minAge":164,"maxAge":138,"enrollmentInfo":375,"targetDuration":4,"studyType":55,"phases":377,"briefSummary":378,"conditions":379,"keywords":381,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":386,"lastUpdatePostDateStruct":387,"startDateStruct":389,"completionDateStruct":391,"leadSponsor":393,"locationsCount":395},"100415814","remediation-program-via-a-serious-game-for-the-cognitive-functions-of-multiple-sclerosis-patients-100415814","NCT04694534","Remediation Program Via a \"Serious Game\" for the Cognitive Functions of Multiple Sclerosis Patients","e-SEP Cognition: Effectiveness of a Remediation Program Via a \"Serious Game\" on the Cognitive Functions of Multiple Sclerosis Patients: Controlled, Randomized, Multicentric Trial","E-SEP","Inclusion Criteria:\n\n* Relapsing-remitting or progressive multiple sclerosis people defined according to Mc Donald's criteria revised in 2005\n* Age between ≥ 18 and ≤ 65 years old\n* Cognitive complaint, with at least one deficient score at the initial neuropsychological examination (\\\u003C5th percentile of the reference group), one of the scores of which concerns at least one BICAMS test\n* Have not had a definite relapse for at least 6 weeks\n* Be at least 4 weeks away from a corticosteroid bolus\n* Lack of neuroleptic treatment\n* Patient with an Internet connection\n* Signed informed consent\n\nExclusion Criteria:\n\n* Severe cognitive deficit defined by obtaining a deficit score in more than six cognitive processes at the initial neuropsychological assessment.\n* Neuropsychological care\n* Inability to receive oral and written information\n* Inability to use the software (due in particular to motor and \u002F or sensory difficulties),\n* Neurological or psychiatric comorbidity, other than MS and anxiodepressive syndrome\n* Patient with severe anxiodepressive syndrome (BDI\\> 27)\n* Participation in an interventional study on cognitive functions\n* Patient under legal protection, guardianship or curatorship\n* Pregnant or breastfeeding women",{"count":376,"type":23},150,[57],"The main goal of this study is to assess the effectiveness of a cognitive remediation program based on a \"serious game\" on the information processing speed evolution and the process of learning via episodic memory in multiple sclerosis patients.",[304,28,380],"Learning",[382,383,384,385],"Multiple sclerosis","Serious game","Episodic memory learning capacities","Information processing speed capacities","2025-09-03",{"date":388,"type":35},"2025-09-04",{"date":390,"type":35},"2021-10-08",{"date":392,"type":23},"2027-03-01",{"name":394,"class":42},"Lille Catholic University",6,{"id":397,"slug":398,"hasResults":11,"nctId":399,"briefTitle":400,"officialTitle":401,"acronym":4,"eligibilityCriteria":402,"healthyVolunteers":17,"sex":18,"minAge":164,"maxAge":403,"enrollmentInfo":404,"targetDuration":4,"studyType":55,"phases":406,"briefSummary":407,"conditions":408,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":411,"lastUpdatePostDateStruct":412,"startDateStruct":414,"completionDateStruct":416,"leadSponsor":418,"locationsCount":43},"100510704","mri-neurofeedback-and-brain-circuits-related-to-motivation-in-healthy-participants-100510704","NCT05929898","MRI Neurofeedback and Brain Circuits Related to Motivation in Healthy Participants","Bridging Scales to Understand Endogenous Neuromodulation and Its Regulation","Inclusion Criteria:\n\n* Age between 18 and 45 years\n* Male or female\n* Right-handed\n* In good general health\n* Women of childbearing capacity: use of effective method of birth control\n\nExclusion Criteria:\n\n* Current or diagnosis within past six months of an DSM-V Axis I or Axis II disorder (self-reported)\n* CES-D score of 20 or higher (indicating significant current depression symptoms)\n* Current or past six month use of prescription medications indicated for psychiatric conditions (e.g.,depression, anxiety)\n* Current serious medical illness (self-reported)\n* Head injury resulting in loss of consciousness\n* For participants age \\> 59 years, a total scaled score \\\u003C 8 on the Dementia Rating Scale-2.\n* A clinically-defined neurological disorder including, but not limited to:\n* Any condition likely to be associated with increased intracranial pressure\n* Space occupying brain lesion\n* History of stroke\n* Transient ischemic attack within two years\n* Cerebral aneurysm\n* Dementia\n* Mini Mental Status Exam (MMSE) score of \\\u003C24\n* Parkinson's disease\n* Huntington's disease\n* Multiple sclerosis\n* Presence of cochlear implants or other implanted electronic devices or non-removable metal (e.g., non-removable piercing, IUD)\n* History of an eye injury involving metal. Participants who worked with metal may be allowed to participate on a case-by-case basis with prior written approval from BIAC.\n* Claustrophobia or unwillingness to tolerate the confinement associated with being in the MRI scanner.\n* Weight of more than 250 pounds","45 Years",{"count":405,"type":23},190,[57],"The purpose of this research study is to understand how healthy individuals self-regulate motivation by observing brain activity using magnetic resonance imaging (MRI).",[409,28,410],"Motivation","Self-regulation","2025-08-21",{"date":413,"type":35},"2025-08-22",{"date":415,"type":35},"2023-07-30",{"date":417,"type":23},"2026-09-09",{"name":419,"class":42},"Duke University",{"id":421,"slug":422,"hasResults":11,"nctId":423,"briefTitle":424,"officialTitle":425,"acronym":4,"eligibilityCriteria":426,"healthyVolunteers":17,"sex":18,"minAge":427,"maxAge":138,"enrollmentInfo":428,"targetDuration":4,"studyType":55,"phases":430,"briefSummary":431,"conditions":432,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":434,"lastUpdatePostDateStruct":435,"startDateStruct":437,"completionDateStruct":439,"leadSponsor":441,"locationsCount":43},"100480892","use-muscadine-wine-nutraceuticals-to-improve-brain-health-cognition-and-mental-health-100480892","NCT05541887","Use Muscadine Wine Nutraceuticals to Improve Brain Health, Cognition, and Mental Health","Acute and Chronic Impacts of Muscadine Wine Polyphenols on Cognition, Memory, Mood, and Anxiety in Adults Over 50 Years of Age","Inclusion Criteria:\n\n* Healthy\n* BMI (18.5-29.9)\n* Body weight ≥110 pounds\n\nExclusion Criteria:\n\n* Pregnancy\n* Breast-feeding\n* Smokers\n* Diabetic\n* Heavy drinkers\n* Subjective but not clinically diagnosed cognitive impairment (Montreal cognitive assessment score \\\u003C26),\n* Inability to understand the cognitive function tasks\n* Intake of medication that might influence the outcome of the study (e.g. psychostimulant)\n* cannabis product user\n* Clinically diagnosed mental illnesses\n* Cardiovascular and neurological disorders\n* Uncontrolled hypertension","50 Years",{"count":429,"type":23},25,[57],"Previous studies have shown that polyphenol-rich foods can positively affect cognitive functions, memory, and mood in humans. We hypothesize that both acute and chronic intake of muscadine wine polyphenols will improve cognitive performance and mood through regulating the HPA axis, alleviating inflammation and oxidative stress, and\u002For inhibiting monoamine oxidase activities",[239,28,433,278],"Mood","2025-06-09",{"date":436,"type":35},"2025-06-12",{"date":438,"type":35},"2023-08-30",{"date":440,"type":23},"2026-12",{"name":442,"class":42},"University of Florida",{"id":444,"slug":445,"hasResults":11,"nctId":446,"briefTitle":447,"officialTitle":448,"acronym":449,"eligibilityCriteria":450,"healthyVolunteers":17,"sex":18,"minAge":164,"maxAge":4,"enrollmentInfo":451,"targetDuration":4,"studyType":55,"phases":453,"briefSummary":454,"conditions":455,"keywords":4,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":461,"lastUpdatePostDateStruct":462,"startDateStruct":464,"completionDateStruct":466,"leadSponsor":468,"locationsCount":4},"100585468","adaptation-and-normalization-of-a-verbal-episodic-memory-test-in-french-sign-language-100585468","NCT06902753","Adaptation and Normalization of a Verbal Episodic Memory Test in French Sign Language","Adaptation and Normalization of a Verbal Episodic Memory Test (16-item Free and Cued Recall \u002F RL-RI 16) in French Sign Language","RL-RI-LSF","Inclusion Criteria:\n\n* Person aged ≥ 18 yo\n* with severe or profound deafness (hearing loss ≥ 70 decibels)\n* whose main language is French Sign Language\n* able to consent in writing after a clear explanation of the procedure\n* affiliated to the French Healthcare system (Sécurité Sociale) through self or another person\n\nNon-inclusion criteria:\n\n* person with a medical history in neurology (stroke, traumatic brain injury, dementia) or psychiatry bipolar syndrom or schizophrenia that would not be medicated, severe depression)\n* persons with medical developmental backgroung (e.g genetic syndrome)\n* person with cancer history needing chemotherapy\n* person with a diagnosed and untreated sleeping trouble\n* person drinking \\> 10 glasses of alcohol per week or using drugs on a daily basis\n* person with visual issues\n* person under 18yo or unable to take decisions for self\n\nExclusion Criteria:\n\nA score ≤ 20\u002F28 or 17\u002F28 at the MMS-LS test, depending on the schooling of the participant (20\u002F28 for participants with a degree, 17\u002F28 for participants without a degree)",{"count":452,"type":23},120,[57],"To date, neuropsychological assessment of deaf signing persons is complicated by a lack of resources, especially the absence of tools available in French Sign Language (LSF). This is due to perceptual and cultural differences, and in particular the linguistic differences between French and LSF.\n\nThis lack of resources significantly hinders access to care for deaf patients, as neuropsychological assessment is often a key clinical criterion in the diagnosis of certain neurological pathologies (Alzheimer's disease in particular) and enables coherent care plans to be drawn up, for example in the aftermath of strokes or traumatic brain injuries.\n\nIn particular, episodic memory (which refers to the ability to memorise information anchored in a specific context) is a cognitive domain that is sensitive to pathologies such as Alzheimer's disease, but it is not currently possible to assess it with deaf signing patients.\n\nThe aim of this study is to create a memory assessment test adapted to a deaf population that expresses in LSF and to normalize this test on this same population.\n\nThe aim is to provide a diagnosis assessment tool, which currently does not exist in France, to improve access to care for deaf people. This project could then be extended to the creation of tests for other cognitive domains (executive functions, attention, social cognition, etc.) and to prospects for cognitive remediation.\n\nThe 16-item Free and Cued Recall test (RL-RI 16) is the best choice because it is easy to use and accurate enough to assess each stage of episodic memory. These qualities make it a decisive tool in certain differential diagnosis.\n\nIn order to select the most relevant signs, lexical lists by frequency in LSF will be drawn up during a preliminary phase, during which the participants will have to give, in one minute, the maximum number of signs belonging to different categories (animals, vegetables, clothes...). These lists will be used to select the most relevant signs according to their frequency (neither too common nor too rare), based on the same principle as RL-RI 16.\n\nIt will then be standardised on deaf adults, for whom LSF is the main language, with no cognitive impairment, across France, via the various Deaf Care Units, with the help of French \u002F LSF interpreters. Working with different centers in France will make it possible to recruit a larger and more representative number of participants, and to be more sensitive to any regional effects.",[456,28,457,458,459,460],"Neuropsychological Tests","Alzheimer Disease","Deafness","Sign Language","Cognitive Impairment","2025-03-24",{"date":463,"type":35},"2025-03-30",{"date":465,"type":23},"2025-04",{"date":467,"type":23},"2027-04",{"name":469,"class":42},"Poitiers University Hospital",{"id":471,"slug":472,"hasResults":11,"nctId":473,"briefTitle":474,"officialTitle":475,"acronym":4,"eligibilityCriteria":476,"healthyVolunteers":17,"sex":18,"minAge":427,"maxAge":477,"enrollmentInfo":478,"targetDuration":4,"studyType":55,"phases":480,"briefSummary":481,"conditions":482,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":483,"lastUpdatePostDateStruct":484,"startDateStruct":486,"completionDateStruct":488,"leadSponsor":490,"locationsCount":43},"100584486","effect-of-daily-mixed-spice-consumption-on-memory-function-100584486","NCT06889961","Effect of Daily Mixed Spice Consumption on Memory Function","Effect of Daily Mixed Spice Consumption on Memory in Middle-Aged and Older Adults with Age-related Cognitive Decline: a Pilot Study","Inclusion Criteria:\n\n1. Participants are required to have clinical histories consistent with normal aging or mild cognitive impairment (MCI).\n2. Age 50 to 80 years.\n3. Adequate visual acuity and hearing to allow neuropsychological testing.\n4. Screening laboratory tests without significant abnormalities that might interfere with the study.\n\n   \\-\n\nExclusion Criteria:\n\n1. Diagnosis of probable Alzheimer's disease or any other dementia (e.g. vascular, Lewy body, frontotemporal)\n2. Evidence of other neurological or physical illness that can produce cognitive deterioration. Determination of dementia will be based on the clinical evaluation including assessment of functional abilities, and cognitive screening (using the Mini Mental State Examination\n3. Evidence of Parkinson's disease as determined by the motor examination (items 18-31) of the Unified Parkinson's Disease Rating Scale \\[38\\].\n4. Uncontrolled hypertension (systolic blood pressure (BP) \\> 170 or diastolic BP \\> 100).\n5. Consume spices regularly \\> 5g day\n6. Allergy or sensitivity to spices. Subjects will be excluded if there is a prior history of such sensitivity. Since these foods are commonly eaten and allergies are rare, subjects should be aware of this sensitivity prior to entering the study. To determine this, a positive history of spices ingestion without incident will be requested. In addition, any subject with a history of allergy or anaphylaxis of any kind will be excluded.\n7. Current diagnosis of any major psychiatric disorder according to the DSM-IV TR criteria (APA, 2000).\n8. Current diagnosis or alcoholism or substance addiction.\n9. Eating a high fiber\u002Fpolyphenol diet or taking any medication or dietary supplement which interfere with the absorption of polyphenols.\n10. Frequently using prebiotics, probiotics, yogurt, and\u002For any fiber supplements","80 Years",{"count":479,"type":23},50,[57],"The aging process entails a multitude of structural and functional alterations within the brain, culminating in a gradual and progressive decline in cognitive function. Recent research has indicated that various spices may hold the key to enhancing brain health and combating the effects of aging on cognitive abilities. The hypothesis is that a mixture of spices, acknowledged for their reported memory protection potential, may yield a more potent beneficial effect on memory function than a single spice. The spice mixture will be used at culinary dose, and therefore side effects are anticipated. In this study, the effects of spice mixture will be evaluated, as well as their anti-oxidant, and anti-inflammatory properties. The proposed pilot study will include 50 adults (ages 50-80), exhibiting typical age-related mild cognitive decline, excluding dementia or major neurocognitive disorders. They will be randomized 1:1 assigned into a daily intake of either 4.00 g spice mixture capsules or 4.00 g maltodextrin capsules over 3 months, and explore the sustainable effect over 3 additional months. The changes in symptoms of cognition, fatigue, and mood symptoms of the spice group vs. placebo group will be compared. The outcome of the investigation of the effects of mixed spice consumption will provide important novel information on dietary recommendation of spice to preserve cognitive function in aging population.",[28,309],"2025-03-20",{"date":485,"type":35},"2025-03-21",{"date":487,"type":35},"2025-02-21",{"date":489,"type":23},"2027-02-21",{"name":491,"class":42},"University of California, Los Angeles",{"id":493,"slug":494,"hasResults":11,"nctId":495,"briefTitle":496,"officialTitle":497,"acronym":4,"eligibilityCriteria":498,"healthyVolunteers":17,"sex":18,"minAge":20,"maxAge":112,"enrollmentInfo":499,"targetDuration":4,"studyType":55,"phases":501,"briefSummary":502,"conditions":503,"keywords":507,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":510,"lastUpdatePostDateStruct":511,"startDateStruct":513,"completionDateStruct":515,"leadSponsor":516,"locationsCount":72},"100498560","home-sleep-therapy-for-older-adults-with-mci-100498560","NCT05771844","Home Sleep Therapy for Older Adults With MCI","Home Sleep Therapy System for Mild Cognitive Impairment","Inclusion Criteria:\n\n* For participant with Amnestic MCI, the inclusion age range is 55-85 years old.\n* For healthy volunteers without MCI, the inclusion age range is 40-80 years old.\n\nExclusion Criteria:\n\n* History of seizures\n* History of epilepsy\n* History of mod\u002Fsevere brain injury or trauma (including neurosurgery)\n* History or presence of significant neurological disease such as Parkinson\n* History of Electroconvulsive Therapy (ECT)\n* Presence of severe insomnia\n* Presence of untreated sleep apnea\n* Presence of severe anxiety or depression\n* Medications that may affect the EEG\n* History of stroke\n* Sensitivity or allergy to lidocaine or silver\n* Presence of active suicidal ideation\n* Presence of metal in head or implants or medication infusion device\n* Pregnancy\n* Adverse reaction to TMS",{"count":500,"type":23},60,[57],"The goal of this clinical trial is to learn about the ability of non-invasive brain stimulation during sleep to enhance people's deep sleep and its potential benefit on memory in people with mild cognitive impairment via home use sleep therapy device (SleepWISP) as well as learn about biomarkers associated with Alzheimer disease (AD). The clinical trial aims to answer the following main questions:\n\n1. Whether the non-invasive transcranial electrical stimulation (TES) delivered by SleepWISP could provide short-term enhancement of deep sleep in a single night in the target population.\n2. Whether TES delivered by SleepWISP could enhance deep sleep over multiple nights in the target population.\n3. Whether enhance on deep sleep could improve memory performance in the target population.\n\nParticipants will be asked to wear non-invasive and painless devices that record their brain activity during sleep along with an actigraphy watch that measures their movement throughout the day. In addition, blood samples or nasal swab assays will be collected from participants multiple times during the study.",[504,61,505,506,28],"Mild Cognitive Impairment","Transcranial Electrical Stimulation","Machine Learning",[508,509],"Slow Wave Sleep","NREM N3 Sleep","2025-02-14",{"date":512,"type":35},"2025-02-17",{"date":514,"type":35},"2023-02-08",{"date":126,"type":23},{"name":517,"class":224},"Brain Electrophysiology Laboratory Company"]